SynthesisSchizophrenia bulletin2026
Short-, Medium-, and Long-Term Cardiometabolic Outcomes in First-Episode Psychosis: A Systematic Review and Meta-analysis.
Synthesis in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIndividuals with first-episode psychosis (FEP) experience increased cardiometabolic risks, contributing to reduced life expectancy. While metabolic disturbances are well described in chronic schizophrenia, their trajectory from first presentation, before or with minimal antipsychotic exposure, through to long-term follow-up remains incompletely characterized.
objectiveTo synthesize evidence on progression of cardiometabolic outcomes in FEP cohorts from before initiation of antipsychotic medication to up to 10 years of follow-up. STUDY
designFollowing PRISMA and MOOSE guidelines (PROSPERO: CRD42023431072), Medline, Embase, PsycInfo, and CINAHL+ were searched to July 2025 for studies of FEP cohorts with ≤28 days of antipsychotic exposure at baseline. Outcomes included weight, glucose, lipids, blood pressure, metabolic syndrome (MetS), diabetes, and cardiovascular disease (CVD). Random-effects meta-analyses were stratified by follow-up duration. As post-baseline exposure was not quantified, follow-up estimates reflect outcomes under routine care. STUDY
resultsFrom 2601 unique articles, 82 studies were included. Obesity and MetS prevalence increased from 5.4% and 8.5%, respectively at baseline, to 26.6% and 18.2% at 1-3 years, whereas type 2 diabetes increased from 0.5% to 5.0% by >5 years. Lipid abnormalities emerged early, while blood pressure changes were minimal, and CVD hospitalization prevalence was 1.4% at 5-10 years. Weight increased by +2.5 kg at 4-8 weeks and + 13.4 kg at >5 years, with parallel increases in BMI and waist circumference.
conclusionsCardiometabolic deterioration begins within weeks of FEP onset and accumulates over time, indicating the need for early prevention, sustained monitoring, integrated metabolic care, and patient education throughout the course of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.